Khiron Life Sciences Corp. (TSXV: KHRN) announced on Friday after the closing bell that its chief financial officer Joel Friedman has resigned. The company’s board has tapped the services of fractional CFO and accounting services provider, RTB LLP, for the interim.
The announcement comes weeks after the firm reported its renewal of the share buyback program. Although deemed as a renewal, the firm continued to expand the share count multiple times over the last year.
Friedman stepped in as CFO on October 16, 2020, just under a year ago. He replaced Wendy Kaufman who served as CFO since July 2019 until her resignation “to return to the mining industry where she has spent the greater part of her executive career”.
In a press release about his CFO appointment back in October 2020, Friedman was described as “the natural successor” to Kaufman after working closely with her since he started in the firm in December 2019 as finance and treasury director. He was touted to bring his 10 years of international financial experience, including his former role as the vice president for finance at cannabis firm CannTrust.
The cannabis firm is tapping RTB LLP, represented by Swapan Kakumanu, for the role of interim CFO effective immediately. According to the financial agency’s website, Kakumanu “has more than 25 years of senior finance and operations experience”. He has also served in senior management roles in different fields, including high-growth technology, manufacturing, blockchain, medical device, and oil field services industries.
The cannabis firm said Friedman will remain with the company until October 31, 2021, to provide transitional support.
Khiron Life Sciences last traded at $0.275 on the TSX Venture.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
